COX-2 Retrospective Study Prompts Review By FDA, Kaiser On Merck’s Vioxx
Executive Summary
A retrospective study conducted on COX-2s and NSAIDs has prompted reviews by FDA and Kaiser Permanente on the use of Merck's Vioxx (rofecoxib)
You may also be interested in...
FDA Postmarketing Surveillance System Adds Kaiser Retrospective Database
FDA will have access to four population-based databases for safety surveillance through its cooperative agreement program beginning in FY 2006, including the newly added Kaiser Permanente California registry
FDA Postmarketing Surveillance System Adds Kaiser Retrospective Database
FDA will have access to four population-based databases for safety surveillance through its cooperative agreement program beginning in FY 2006, including the newly added Kaiser Permanente California registry
Risk Management Guidance Suggests Advisory Cmte Review For RiskMAPs
FDA recommends that advisory committees weigh in on whether a risk minimization action plan is appropriate for a particular drug